Sugi Predict

Sugi Predict / Compounds / SCHEMBL217338

SCHEMBL217338

SCHEMBL217338

COc1cc2ncnc(O)c2cc1OC(C)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 2/20 0.52
▸ EGFR P00533 4/20 0.52
▸ ACHE P22303 1/20 0.49
▸ BACE1 P56817 1/20 0.49
▸ TNFSF11 O14788 1/20 0.49
▸ KDR P35968 10/20 0.46
▸ RET P07949 7/20 0.46
▸ JAK3 P52333 2/20 0.46
▸ GAK O14976 1/20 0.46
▸ RIPK2 O43353 1/20 0.46
▸ STK10 O94804 1/20 0.46
▸ FLT3 P36888 1/20 0.46
▸ AAK1 Q2M2I8 1/20 0.46
▸ Q6ZSR9 Q6ZSR9 1/20 0.46
▸ SLK Q9H2G2 1/20 0.46
▸ IRAK4 Q9NWZ3 1/20 0.46
▸ RPS6KA6 Q9UK32 1/20 0.46
▸ ALK Q9UM73 1/20 0.46
▸ LCK P06239 1/20 0.45
▸ KIF5B P33176 5/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28016254 0.99 PDE10A (0.51) PDE10AEGFRACHEBACE1TNFSF11
SCHEMBL2476964 0.87 RET (0.55) PDE10AEGFRKDRRETJAK3
SCHEMBL24714036 0.86 ENPP1 (0.48) EGFRENPP1
SCHEMBL18013038 0.85 PDE10A (0.46) PDE10AEGFRACHEBACE1KDR
SCHEMBL8777 0.84 ENPP1 (0.63) PDE10AEGFRACHEBACE1TNFSF11
SCHEMBL3427630 0.84 ENPP1 (0.63) PDE10AEGFRACHEBACE1TNFSF11
Hydrochloric Acid SCHEMBL9097 0.83 ENPP1 (0.62) PDE10AEGFRACHEBACE1TNFSF11
SCHEMBL5231086 0.80 EPHA2 (0.43) EGFRACHEBACE1KDR
SCHEMBL7225895 0.80 EGFR (0.49) EGFRIRAK4LCK
SCHEMBL5230842 0.80 KDR (0.43) EGFRACHEBACE1KDRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110590683-B Preparation method of intermediate of targeting drug AZD3759 山东四环药业股份有限公司 2022-08-19 — — CN claimed
CN-110590683-A Preparation method of intermediate of targeting drug AZD3759 山东四环药业股份有限公司 2019-12-20 — — CN claimed
EP-3941459-B1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2026-05-06 — — EP disclosed
CN-113924092-B Quinoline and quinazoline compounds and methods of use thereof 斯汀格瑞治疗股份有限公司 2025-03-18 — — CN disclosed
US-20240382599-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-11-21 — — US disclosed
CN-112996784-B Indole derivatives and their use in medicine 北京越之康泰生物医药科技有限公司 2023-05-30 — — CN disclosed
CN-110590683-B Preparation method of intermediate of targeting drug AZD3759 山东四环药业股份有限公司 2022-08-19 — — CN disclosed
CN-110590683-B Preparation method of intermediate of targeting drug AZD3759 山东四环药业股份有限公司 2022-08-19 — — CN disclosed
WO-2022170043-A1 QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF ACCUTAR BIOTECHNOLOGY, INC. (US) 2022-08-11 — — WO disclosed
US-11407729-B2 Quinoline and quinazoline compounds and methods of use thereof Stingray Therapeutics, Inc. (US) 2022-08-09 — — US disclosed
US-11377451-B2 Compositions and methods for treating cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-07-05 — — US disclosed
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA, INC. (US) 2009-01-08 — — US disclosed
US-7452901-B2 Anti-cancer phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-11-18 — — US disclosed
US-7452901-B2 Anti-cancer phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-11-18 — — US disclosed
US-7417055-B2 Kinase inhibitory phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-08-26 — — US disclosed
US-7417055-B2 Kinase inhibitory phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-08-26 — — US disclosed
EP-1567506-A4 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA INC (US) 2007-06-20 — — EP disclosed
EP-1567506-A2 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS Array Biopharma, Inc. (US) 2005-08-31 — — EP disclosed
US-20050101617-A1 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA, INC. 2005-05-12 — — US disclosed
WO-2004046101-A2 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA, INC. (US) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382599-A1 EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE TBK1, EGFR, CBL PDE10A 4432/4885EGFR 2/4885ACHE 3034/4885
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ERBB2, GRB2, EGFR PDE10A 3145/4885EGFR 3/4885ACHE 4808/4885
US-11377451-B2 Compositions and methods for treating cancer TP53, EGFR, SLC2A1 PDE10A 3326/4885EGFR 2/4885ACHE 2807/4885
US-20050101617-A1 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ERBB2, GRB2, EGFR PDE10A 3145/4885EGFR 3/4885ACHE 4808/4885
US-11407729-B2 Quinoline and quinazoline compounds and methods of use thereof ENPP1, ENPP3, PDE7A PDE10A 482/4885EGFR 4544/4885ACHE 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.